32 results about "Hair cell" patented technology

This utility model discloses a low-noise centrifugal pump for petrochemical applications, comprising a centrifugal pump body, an impeller movably mounted inside the pump body with an impeller shaft mounted on it, an inlet pipe at the front of the pump body, a drain pipe at the top of the pump body, and a low-noise mechanism wrapped around the outside of the pump body. The low-noise mechanism consists of noise reduction covers A, B, C, and D. Noise reduction cover B is fixedly mounted at one end of noise reduction cover A, and noise reduction cover D is fixedly mounted at one end of noise reduction cover C. This low-noise centrifugal pump for petrochemical applications features modularly designed noise reduction covers that can be quickly installed using a mounting bracket without complex tools or specialized skills, reducing the noise level generated by the centrifugal pump and preventing damage to the inner ear hair cells of factory workers, thus avoiding irreversible hearing loss. The rock wool itself has a porous fiber structure, primarily absorbing mid-to-high frequency noise.

The invention relates to the technical field of noise deafness susceptibility grading, in particular to a noise deafness susceptibility grading method and system based on a multi-band hearing threshold, and the method comprises the steps: presetting measurement frequency points, generating a measurement frequency point set according to a sequence from high frequency to low frequency, and completing M times of independent measurement for each frequency point; recording a tested subjective response timestamp, and generating a confidence value label; an otoacoustic emission signal in a tested ear canal is collected in real time, a time domain signal with the highest confidence coefficient of a single frequency point is extracted, spectrum features are calculated, and otoacoustic emission joint parameters are constructed. According to the method, the time sequence diffusion rule from high frequency to low and medium frequency hair cell damage can be comprehensively captured, the identification accuracy of potential auditory impairment is remarkably improved, the propagation mechanism from high frequency damage to intermediate frequency can be simulated by constructing the physically constrained spectrum migration operator, and otoacoustic emission time domain-frequency domain joint parameters and physiological indexes are combined, so that the identification accuracy of the potential auditory impairment is improved. And individualized and dynamic injury risk prediction is realized.

The invention belongs to the technical field of transgenic and biomedical research tools, and particularly relates to a method for constructing a transgenic fish system based on a Tol2 transposon system, which comprises the following steps: constructing a myo6b-lhfpl5b-DsRed plasmid by using myo6b as a promoter, lhfpl5b as a target gene and DsRed as a red fluorescent protein tag through a microinjection method, and constructing a Tol2 transposon system-based transgenic fish system. Co-injecting the plasmid containing the Tol2 transposase mRNA and the Tol2 transposase mRNA into a fertilized egg of an AB zebra fish strain, and screening generation by generation to obtain a transgenic fish strain with stable inheritance MET channel gene lhfpl5b marked hair cells. The spatio-temporal dynamic visualization of the living whole fish to the lhfpl5b is realized, the deafness-causing molecular pathway is clarified, and an in-vivo platform is provided for drug screening and intervention strategies.

The invention discloses an HSP70-targeting chimeric antigen receptor-macrophage and application thereof in treatment of noise-induced hearing loss, an extracellular domain of the HSP70-targeting chimeric antigen receptor comprises an HSP70 specific binding fragment, an intracellular domain comprises an IL-4 signal channel functional element, a signal switch type CAR structure of the HSP70 is formed, and the macrophage can be used for treating noise-induced hearing loss, so that the HSP70-targeting chimeric antigen receptor-macrophage can be used for treating noise-induced hearing loss. The HSP70-targeted chimeric antigen receptor-macrophage can be used for preparing the HSP70-targeted chimeric antigen receptor-macrophage, is used for mediating polarization of the macrophage to an M2 type and exerting an anti-inflammatory function, is proved to be capable of specifically responding to an inner ear inflammation microenvironment, switching an anti-inflammatory phenotype and protecting hair cells and auditory nerves, can be used for treating noise-induced hearing loss, and can be used for preparing the HSP70-targeted chimeric antigen receptor-macrophage. The limitation that traditional hearing-aid equipment supports treatment on symptoms is broken through, and the hearing-aid device has a remarkable application prospect.

The embodiment of the invention provides a cell guiding device, and the device comprises a receiving coil which is used for receiving a radio frequency signal transmitted by an in-vitro energy supply device; the stimulator is electrically connected with the receiving coil and is used for generating an electrical stimulation pulse according to the radio frequency signal; the electrode array is used for being arranged in the cochlea and electrically connected with the stimulator; the electrode array is used for applying the electrical stimulation pulse to hair cells in the cochlea so as to stimulate the hair cells to proliferate and differentiate. According to the technical scheme provided by the embodiment of the invention, the electrical stimulation pulse is generated according to the in-vitro radio frequency signal and is applied to the hair cells in the cochlea, so that accurate and efficient electrical stimulation on the hair cells can be realized. Meanwhile, the implanted design is adopted to directly act on the hair cells in the cochlea, so that the trauma to the body can be reduced, and the safety and comfort of treatment are improved.

The disclosure provides polynucleotides containing regions of the Myosin 15 (Myo15) promoter, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.

The application discloses a kind of based on bionic lateral line's curved optical fiber multi-parameter sensor, one end of input optical fiber is connected with light source emission end, the other end is sequentially penetrated through the sensor base and artificial cilium cantilever beam and bare optical fiber fixed connection;The other end of bare optical fiber is fixedly connected with output optical fiber;The other end of output optical fiber is penetrated through artificial cilium cantilever beam and is connected with the light source receiving end communication connection.The sensor of the application can monitor the size of flow velocity, flow velocity direction, salinity and other multiple parameters simultaneously, and can meet the multidimensional monitoring demand under complex marine environment.Meanwhile, by imitating the structure of fish lateral line hair cell, using flexible artificial cilium cantilever beam as core perception element, the accurate detection of water flow velocity size and direction can be realized.In addition, the sensor is directly contacted with fluid through bare optical fiber part, and the detection of fluid salinity is realized by using the difference of different fluid refractive index.

The invention provides Chinese herbal medicine hair-nourishing and color-protecting cream, and belongs to the technical field of hair-protecting products. The invention relates to a Chinese herbal medicine hair nourishing and color protecting cream which can effectively solve various hair problems, such as alopecia, white hair, scurf, itching in head, folliculitis, dry and dry hair and the like. The hair nourishing cream provided by the invention is safe, non-toxic and free of side effects. When in use, the traditional Chinese medicine composition is externally applied to hair follicles at the roots of hair, and through the principle of transdermal administration, the traditional Chinese medicine composition deeply permeates into the skin layers of the hair follicles, activates hair cells and enables effective components in the Chinese herbal medicines to fully permeate into the hair follicles, so that the traditional Chinese medicine composition has a remarkable repairing effect on various hair problems and helps more people to get rid of hair troubles.

Disclosed herein are methods for treating and / or preventing AG-induced hearing loss. The methods involve downmodulating GABARAP disclosed herein to thereby treat and / or prevent AG-induced hearing loss. Also disclosed herein are methods for treating and / or preventing AG-induced hearing loss in a patient in need thereof comprising downmodulating GABARAP, disclosed herein, to thereby treat and / or prevent AG-induced hearing loss in a patient in need thereof.

The invention relates to the technical field of sustained-release preparation, in particular to a microcrystalline sustained-release preparation and a preparation method thereof.The sustained-release preparation comprises a core composed of edaravone rodlike microcrystals and a shell composed of 2-4 double layers, the shell comprises at least one polyethylene glycol-polylysine copolymer inner layer, and the polyethylene glycol-polylysine copolymer inner layer is a polyethylene glycol-polylysine copolymer outer layer. And at least one outer layer of hyaluronic acid modified with a CD44 targeting peptide. The CD44 targeting peptide modified by the shell layer can specifically recognize a CD44 receptor on the surface of an inner ear hair cell, so that the binding efficiency of a preparation, a round window membrane and a target cell is remarkably improved, the diffusion of a drug to non-target tissues is reduced, and the local drug concentration is improved.

Presented herein are techniques that make use of objective measurements obtained in response to acoustic stimulation signals. More specifically, at least one measure of outer hair cell function and at least one measure of auditory nerve function are obtained from a tonotopic region of an inner ear of a recipient of a hearing prosthesis. The at least one measure of auditory nerve function and the least one measure of outer hair cell function are then analyzed relative to one another.

A method for treating hearing loss in a subject in need thereof is provided. The method includes providing a combination of transcription factors to induce generation of a hair cell-like cell, thereby treating the hearing loss in the subject. The generated hair cell-like cells exhibit characteristic of mature functional cells that is useful in cell replacement therapy for autologous transplantation.

Disclosed are compositions and methods for treating diseases of the mammalian eye, and in particular, complications of the retina associated with Usher syndrome 1B (USH1B). Further disclosed are compositions and methods for treating diseases of the mammalian inner ear, and in particular, complications of ear hair cells associated with Usher syndrome 1B (USH1B). The disclosure provides improved AAV-based, dual vector systems that facilitate the expression of full-length proteins whose coding sequences exceed that of the polynucleotide packaging capacity of an individual AAV vector. Described herein are modified hybrid dual vector systems that shift the coding sequence for the MYO7A tail domain from the front-half vector to the back-half vector by altering the split point (e.g., from between exons 23 and 24, to between exons 21 and 22), in order to eliminate the production of truncated MYO7A protein. Further described herein are improved, codon-modified hybrid and overlap vector systems in which putative stop codons and residual sequences in non-coding sequences are removed.

The invention discloses a cell culture device for hair regeneration, which comprises a culture medium in which a culture dish, a cell culture tank and a polystyrene microporous culture plate are arranged, and the culture medium is used for loading hair cells and a culture solution. The device is provided with an end cover, a temperature sensor and a PH sensor are installed on the end cover, and culture environment parameters can be monitored in real time. A PH value buffering assembly is arranged, a buffering solution in a bicarbonate buffering solution tank is conveyed to the culture dish through a water pump, and the PH value is adjusted. The device further comprises a temperature control assembly, a semiconductor chilling plate and a graphene electric heating piece are utilized, a heat conduction plate, a heat conduction copper pipe, heat dissipation fins and a heat dissipation fan are combined, and the culture temperature is adjusted. In the culture process, the sensor continuously monitors, all the components cooperatively work under the control of an external control system, the temperature and the PH value in the culture dish are kept within the range suitable for hair cell growth and regeneration, and effective cell culture support is provided for hair regeneration research.

This invention discloses a hair cell protectant based on a ferritin nanoplatform and its application in treating hearing loss, belonging to the field of biomedicine. The ferritin nanoparticles of this invention, loaded with cimicifugin, include ferritin (Fn) as a carrier and cimicifugin (Ci@Fn) loaded within the ferritin. By loading cimicifugin (Ci), an extract of cimicifugin, into ferritin, it is endowed with additional anti-inflammatory and tissue-protective functions, thereby achieving a more precise and effective therapeutic effect. After injection through the round window membrane (RWM) behind the ear, Ci@Fn is transported to the basement membrane along with the flow of perilymph and endolymph, ultimately targeting the inner ear hair cells (HCs). After entering the hair cells, Ci@Fn is taken up and degraded by lysosomes, releasing cimicifugin (Ci), thereby exerting a protective effect on the hair cells.

The application discloses a chimeric antigen receptor-macrophage targeting HSP70 and application thereof in the treatment of noise-induced hearing loss, wherein the extracellular domain of the chimeric antigen receptor targeting HSP70 comprises an HSP70 specific binding fragment, and the intracellular domain comprises an IL-4 signal pathway functional element, forming a'signal switch type' CAR structure targeting HSP70, which can be used for preparing the chimeric antigen receptor-macrophage targeting HSP70 and mediating the polarization of the macrophage to M2 type and exerting the anti-inflammatory function. It has been verified that the chimeric antigen receptor-macrophage targeting HSP70 can specifically respond to the inner ear inflammatory microenvironment, switch the anti-inflammatory phenotype and protect the hair cells and auditory nerves, and can be used for treating the noise-induced hearing loss, breaking through the limitation of the symptomatic support treatment of the traditional hearing aid device and having a significant application prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of neratinib in preparation of a medicine for preventing and treating noise-induced deafness. According to the specific technical scheme, the application of the neratinib in preparation of the medicine for preventing and treating hearing impairment / deafness is provided. According to the invention, the fact that neratinib can play a hearing protection role by specifically regulating and controlling cochlea immune microenvironment is found for the first time, and the hearing protection role is specifically realized by the following mechanisms: regulating and controlling biological effects such as cell signal channels, inflammatory response and cell stress response, protecting hair cell structures, and reducing cochlea basilar membrane outer hair cell loss caused by noise exposure. Based on the new discovery of the invention, the neratinib can be used for preparing medicines for preventing and treating hearing impairment and deafness caused by noise.

The invention discloses application of cimicifugin in preparation of a medicine for preventing or treating inner ear hair cell injury, and belongs to the technical field of biological medicine. According to the invention, it is found for the first time that a natural compound cimifugin has a definite inner ear hair cell protection effect. By inhibiting hair cell apoptosis and reducing hearing synapse loss and hearing nerve fiber injury, the cimicifugin effectively relieves hair cell injury and hearing function decline caused by cis-platinum and other drugs, noise exposure and aging. The protection mechanism is related to inhibition of activation of a pro-apoptosis signal. The preferred administration mode is local administration, especially delivery through a round window membrane, and the dosage form can be a solution, a suspension or a sustained release preparation. Cell, in-vitro hair cell tissue and animal model experiments prove that the cimicifugin can obviously relieve hair cell damage and improve the auditory function. The invention provides a new drug candidate scheme for preventing and treating sensorineural hearing loss, and has important clinical application value.

To provide a new therapy targeting hair cells for the treatment of sensorineural hearing loss or vestibular dysfunction.SOLUTION: The present disclose provides polynucleotides containing a region of the myosin 15 (Myo15) promoter, as well as vectors containing the same, which can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein can be operably linked to a transgene, such as a transgene encoding a therapeutic protein, to facilitate hair cell-specific expression of the transgene. The polynucleotides described herein can be operably linked to a therapeutic transgene and used in the treatment of a subject having or at risk of developing hearing loss or vestibular dysfunction.SELECTED DRAWING: Figure 1

The present disclosure describes gene therapy systems, and related methods, useful for treating and / or preventing deafness caused by genetic mutation of the TMPRSS3 gene or the LOXHD1 gene. The compositions and methods disclosed herein use adeno-associated viral (AAV) vector gene delivery of TRMPSS3 or LOXHD1 into the inner ear to restore activity of the TMPRSS3 gene or the LOXHD1 gene, respectively, promote hair cell survival and restore hearing in patients suffering from hearing loss. As disclosed herein, the systems and methods may utilize a combination of gene therapy (e.g., molecular therapeutics) for hearing loss caused by a genetic mutation together with implantation of a cochlear implant.

The invention belongs to the technical field of biological medicines, and particularly relates to application of butyric acid-producing enteromonas in prevention and treatment of senile deafness. It is found for the first time that the butyric acid producing enteromonas sp. Has a remarkable hearing protection effect in a senile deafness model; the action mechanism is mainly embodied in that by improving hearing threshold rise caused by aging, the structural integrity of cochlea hair cells is partially protected to relieve arrangement disorder and deletion of outer hair cells, and the number of inner ear spiral neuron ganglions and vascular stripe aging cells is effectively reduced; meanwhile, the high expression of Pvalb key genes and Parvalbumin in neurons and hair cells of spiral ganglions is up-regulated, so that the synergistic effect is achieved by enhancing the sound transmission muscle efficiency of the middle ear, improving the blood vessel microcirculation of the inner ear, stabilizing the hair cytoskeleton and protecting nerves. The invention provides a new candidate strain resource and an intervention target for preventing and treating senile deafness, and has important clinical application prospect and social value.

The application discloses a boron-based composite nanomaterial, a preparation method thereof and application of the boron-based composite nanomaterial in inner ear hair cells. The boron-based composite nanomaterial comprises a dispersion medium, a layered boron-based material with antioxidation, and a targeting peptide chemically connected with the layered boron-based material, the targeting peptide being used for being combined with a side membrane motor protein on the surface of the hair cell. The layered boron-based material in the boron-based composite nanomaterial can eliminate ROS by using the performance of the layered boron-based material itself, and plays an antioxidation role. The targeting peptide in the boron-based composite nanomaterial forms a relatively stable covalent bond with the layered boron-based material, and can specifically target the receptor of the hair cell. After the layered boron-based material is attached to the hair cell, the layered boron-based material enters the inside of the hair cell, plays a high-efficiency antioxidation role under the response of the microenvironment of the hair cell, and realizes directional protection of the hair cell.

The invention belongs to the field of biological medicines, and particularly relates to application of penicillamine in preparation of a medicine for preventing and treating noise-induced deafness. According to the specific technical scheme, the application of the penicillamine in preparing the medicine for preventing and treating hearing impairment / deafness is provided. The hearing disorder and / or deafness is caused by noise. It is found for the first time that penicillamine can play a hearing protection role by specifically regulating a cochlea immune microenvironment, and the hearing protection role is specifically achieved through the following mechanisms: inhibition of T cell activation: interference of a TCR signal channel; the hair cell structure is protected; the cochlea basilar membrane outer hair cell loss caused by noise exposure is reduced. Based on the new discovery of the invention, the penicillamine can be used for preventing and treating hearing impairment and deafness caused by noise.

A method for treating hearing loss in a subject in need thereof is provided. The method includes providing a combination of transcription factors to induce generation of a hair cell-like cell, thereby treating the hearing loss in the subject. The generated hair cell-like cells exhibit characteristic of mature functional cells that is useful in cell replacement therapy for autologous transplantation.

The application belongs to the technical field of bioinformatics, single-cell multi-omics and artificial intelligence, and discloses a tea tree hair phenotype prediction method and system based on machine learning. The method comprises the following steps: firstly, the development trajectory of tea tree epidermis and hair cells is finely analyzed by using single-cell transcriptome sequencing (scRNA-seq), and hair-specific expression gene clusters are accurately positioned. Combined with a high-density genetic map, the hair-specific expression genes screened at the single-cell level are subjected to expression quantitative trait locus (eQTL) mapping, 111 core single nucleotide polymorphism (SNP) sites most significantly related to hair development are strictly screened from the whole genome, and a Core-111 feature set with extremely reduced dimension is constructed. Subsequently, a variety of regression algorithms are evaluated in parallel, and an arithmetic mean ensemble learning model with ridge regression and gradient boosting regression as base learners is constructed.

Provided are nucleic acid sequences that result in the specific expression of a gene in intra-cochlear hair cells, and their use in gene therapy, especially in the treatment of hereditary hearing loss associated with a defect in intra-cochlear hair cells.

The invention belongs to the field of medical application, and particularly relates to application of troxerutin in a medicine for preventing and treating ototoxicity induced by cis-platinum. The invention provides an application of troxerutin in a medicine for preventing and treating ototoxicity induced by cis-platinum, research finds that troxerutin can remarkably inhibit ROS accumulation, Fe overload and GPX4 reduction induced by cis-platinum, so that excessive accumulation of active oxygen and ferroptosis in hair cells are blocked, the auditory function is improved, troxerutin remarkably inhibits cell apoptosis induced by cis-platinum, and the troxerutin can be used for preventing and treating ototoxicity induced by cis-platinum. And a new way is provided for transformation application of traditional Chinese medicine micromolecules in ear toxicity prevention and treatment.

Embodiments of the present disclosure relate to an electronic headset system which is wirelessly controlled and is used to treat a tinnitus disorder. The system includes an electronic headset and an electronic communication device, such as a smartphone, a wearable device, laptop, tablet, desk top computer, server, and the like or any combination thereof. The electronic headset includes at least one treatment pad and emits complex signals which are converted into vibrations by the treatment pad and are transmitted to a user's cochlea when the electronic headset is worn, thereby alleviating the symptoms of the user's tinnitus disorder. Particularly, complex signals are applied to the Temporal Bone of the skull by the pads positioned in front of the ear, or the tragus, which is the protruding cartilage at the front of the ear. This allows the vibration to be carried by the temporal bone, through conduction to the cochlea and cilia nerves in the cochlea and other parts of the inner ear.

The present invention is an improved method for measuring the electromotile movement of outer hair cells (OHC) which are used in assessing the condition of the OHC and the state of the acoustic path of OHC. The obtained measurement results may be further processed either by comparing them to a standard signal obtained from the electromotile movement of OHC of averaging of a large number of measurements from “normative” people or by comparing them to a model. The measuring method: Stimulated OHC emit acoustic and electromagnetic signals as a result of a stimulus. The method of the invention comprises capturing the emitted electromagnetic signals from the OHC by electrodes placed in close vicinity of an ear of a treated person. The captured signals are transmitted, in the form of a wave file, via electrical connections to a signal processor. The signal processor applies spatial averaging and / or voting algorithm(s) and produces measurement results.

The present invention relates to a pharmaceutical composition for the prevention or treatment of hearing loss containing ammonium lactate as an active ingredient. It has been confirmed that treating hair cells damaged by gentamicin with ammonium lactate increases the number of normal hair cells, and therefore, a pharmaceutical composition containing ammonium lactate as an active ingredient can be used to prevent or treat hearing loss, a side effect of using the antibiotic ammonium lactate.